COPD patients, and asthma patients age 4 and older, in Canada have a new generic treatment option. Mylan is introducing Wixela Inhub (fluticasone propionate and salmeterol inhalation powder).
The product is the first available generic in Canada of GlaxoSmithKline's Advair Diskus, the leading asthma and COPD treatment.
Wixela Inhub was approved by Health Canada in January for the twice daily maintenance treatment of asthma in patients age 4 and older not adequately controlled on long-term asthma control medications or whose disease warrants initiation of treatment with both inhaled corticosteroids and long-acting beta2-agonists; or maintenance treatment of COPD.
Wixela Inhub is available in the 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths for asthma patients and the 250 mcg/50 mcg and 500 mcg/50 mcg strengths for COPD patients.
"We're pleased to offer Wixela Inhub as the first available bioequivalent alternative to Advair Diskus, one of the leading treatments for asthma and COPD management today. Wixela Inhub is the result of a $700 million investment worldwide, including an extensive research and development program. With today's launch in Canada, we are pleased to expand access to this important medicine by providing a more affordable alternative to appropriate asthma and COPD patients," Mylan Canada Country manager David Simpson said.
Advair Diskus had a market value of $113.9 million in Canada, for the 12 months ending Dec. 31, 2019, according to IQVIA.